Atty. Dkt. No. 003211.00099

Form PTO 1595
1-31-82

05-07-2002

102080708

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

To the Honorable Commissioner of Patents & Trademarks: Please record the attached original documents or copies thereof

Kenneth M. Alo, M.D., 4512 Teas, Bellaire, Texas 77401

Claudio Feler, M.D., 950 Audubon Drive
Memphis, Tennessee 38117

4-22-02

Additional name(s) of conveying party(ies) attached?
☐Yes ☒No

2. Name and address of receiving party(ies):

Name: Advanced Neuromodulation Systems, Inc.

Internal Address:

Street Address: 201 Allentown Parkway

City: Allen State: TX ZIP: 75002

Additional name(s) & address(es) attached? ☐ Yes ☒ No

3. Nature of conveyance:
☐ Assignment ☐ Merger
☐ Security Agreement ☐ Change of Name
☒ Other Exclusive License Agreement

Execution Date: August 20, 1998

4. Application number(s) or patent number(s)
If this document is being filed together with a new application, the execution date of the application is :
A. Patent Application No.(s)
B. Patent No.(s) 6,002,964; 6,104,957

Additional numbers attached? ☐ Yes ☒No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Hughes & Luce, L.L.P.

Internal Address: Peter R. Lando, Esq.

Street Address: 1717 Main Street Suite 2800

City: Dallas State: TX ZIP: 75201

6. Total number of applications and patents involved: 2

7. Total fee (37 CFR 3.41):..... $ 80.00

☐ Enclosed
☒ Authorized to be charged to deposit account

8. Deposit account number:
501343
(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.
To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Christopher A. Munns — Name of Person Signing

Signature

4/22/02 — Date

Total number of pages including cover sheet: 6

05/06/2002 TDIAZ1 00000245 501343 6002964
01 FC:581 80.00 CH

Do not detach this portion

Mail documents to be recorded with required cover sheet information to:

Commissioner of Patents and Trademarks
Box Assignments
Washington, D.C. 20231

Public burden reporting for this sample cover sheet is estimated to average about 30 minutes per document to be recorded, including time for reviewing the document and gathering the data needed, and completing and reviewing the sample cover sheet. Send comments regarding this burden estimate to the U.S. Patent and Trademark Office, Office of Information Systems, PK2-1000C, Washington, D.C. 20231, and to the Office of Management and Budget, Paperwork Reduction Project (0651-0011), Washington, D.C. 20503.

Published by THE BUREAU OF NATIONAL AFFAIRS, INC., Washington, D.C. 20037

LICENSE AGREEMENT

THIS LICENSE AGREEMENT (this "Agreement"), dated as of August 20, 1998 (the "Effective Date"), is by and between Kenneth M. Alo, M.D. ("Alo") and Claudio Feler, M.D. ("Feler") (each, a "Licensor" and together, "Licensors"), and Advanced Neuromodulation Systems, Inc., a Texas corporation ("Licensee" or "ANS").

RECITALS

Licensee has developed, and has the right to manufacture and market, certain electrical stimulation systems for the treatment of chronic pain, as well as related products used in various medical applications.

Licensors have developed certain methods or techniques for positioning conventional electrical stimulation electrodes to enable placement at, and stimulation of, particular nerve roots, nerve plexi, and/or peripheral nerves.

Licensors have made one patent application with the United States Patent and Trademark Office to cover their methods of managing chronic pelvic pain, and intend to make further patent applications in the United States and with foreign patent authorities.

Licensee desires to market or develop products based on its existing technology for use in the field addressed by Licensors' patent application and future extensions thereof, and accordingly, Licensee desires to obtain from Licensors, and Licensors are willing to grant to Licensee, the license described in this Agreement.

NOW THEREFORE, in consideration of the mutual covenants and conditions set forth herein, the receipt and sufficiency of which are acknowledged by each party, the parties agree as follows:

3. LICENSE TO LICENSEE

3.1 License. For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Licensors hereby grant Licensee an exclusive, worldwide license and right, with the right to sublicense, to practice the Inventions as particularly described in the Patents, and to develop, make, have made, use, have used, sell and have sold the Products. This license shall not be assigned by Licensee, except to a transferee of all or substantially all of Licensee's business (whether through merger, stock sale, asset sale or otherwise).

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed, signing in their capacities as set forth below.

Kenneth M. Alo, M.D.

Signature 8/22/98

Claudio Feler, M.D.

Signature 8/22/98

ADVANCED NEUROMODULATION SYSTEMS, INC.

By: _____

Name: F. Robert Merrill III

Title: Executive Vice President

Schedule A

See Patent Application attached.

Attorney Docket No.: 14527/01101

"Express Mail" mailing label number EL081810394US

Date of Deposit July 15, 1998
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Derrick Gordon
(Typed or printed name of person mailing paper or fee)

(Signature of person mailing paper or fee)

July 15, 1998
Date of Signature

EPIDURAL NERVE ROOT STIMULATION

FIELD OF THE INVENTION

The present invention relates to a method of managing human chronic pain due to disease, nervous disorders, or like afflicting the pelvic region, and in particular, to a method of applying electrical energy through electrical stimulation electrodes particularly positioned in the lumbosacral region of a patient to inhibit the transmission of chronic pain signals to the brain.